-
You may think that because you're a case manager, you don't need to be aware of the implementation of the new International Classification of Diseases (ICD-10) codes. Or you may think that since they don't take effect until Oct. 1, 2013, you don't have to worry about them yet.
-
A rifamycin antibacterial agent has been approved for treating patients with hepatic encephalopathy (HE). Rifaximin is a minimally absorbed oral antimicrobial that was originally approved in 2004 for the treatment of travelers' diarrhea caused by Escherichia coli. It is marketed by Salix Pharmaceuticals as Xifaxan®.
-
Drug-related hepatotoxicity during treatment for tuberculosis is a common barrier to initiation of antimycobacterial. While most hepatotoxicity results in minimal to no gastrointestinal complaints, some patients experience significant nausea, anorexia, vomiting, or abdominal pain.
-
-
In this issue: New reports about proton pump inhibitors and the effects of gastric suppression, pioglitazone vs vitamin E for non-alcoholic steatohepatitis, metformin and vitamin B12 deficiency, and FDA Actions.
-
Every year about this time, I see a couple of unhappy local residents who present with an intensely pruritic, erythematous papular mystery rash. In contrast to flea bites, which are simple raised papules, the lesions seem umbilicated or have a central bite mark.
-
-
[Editor's note: This is the first part of a two-part series on avoiding liability in contracting. In this month's issue, we tell you about how you can end up contracting with the wrong company and what your liability can be. In next month's issue, we give you specific steps to investigate vendors, and we suggest items to watch for in the contract.]
A h
-
Well, this is a fine mess all us health care providers are all getting into isn't it? I mean, we have oil spills, the earthquakes, and volcanoes and various other sundries out there to make our lives more complicated and miserable.
-
